Abbott Initiates Clinical Study Evaluating Use Deep Brain Stimulation System To Manage Severe Depression
Portfolio Pulse from Benzinga Newsdesk
Abbott has initiated a clinical study to evaluate the use of its deep brain stimulation system for managing severe depression. The U.S. FDA has granted Abbott Breakthrough Device designation for this treatment, which targets treatment-resistant depression (TRD).
September 04, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott has received FDA Breakthrough Device designation for its deep brain stimulation system aimed at treating severe depression. This could position Abbott as a leader in innovative treatments for treatment-resistant depression.
The FDA Breakthrough Device designation is significant as it highlights the potential of Abbott's deep brain stimulation system to address a major unmet medical need. This could lead to increased investor interest and a positive impact on Abbott's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100